Business Standard

FDA new drug approval run rate down in FY20 for most Indian pharma majors

According to analysts, companies are skeptical about entering crowded opportunities

drug, medicine, pharmaceutical, pharma
Premium

Sun Pharma saw a sharp rise in ANDA approvals though, from 37 in FY19 to 45 in FY20 | Photo: Shutterstock

Sohini Das Mumbai
Indian drugmakers have been careful in filing new drug applications with the US regulator. New application submissions as well as withdrawal of filed applications continue as companies focus on rationalising their approach to launching drugs in the US market and choose to focus on comparatively high margin products.

A quick look at the number of abbreviated new drug applications (ANDAs) approvals received by key Indian drug makers from the US Food and Drug Administration  (USFDA) shows that in FY20, most companies have seen a decline in the number of approvals compared to the previous year.

ALSO READ: India

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 31 2020 | 1:52 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com